Editas Medicine Financial Statements
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Editas Medicine revenue and earnings
In fiscal 2025, Editas Medicine generated $40.5 million in revenue, up 25.4% from fiscal 2024. Editas Medicine reported a net loss of $160.1 million, compared with a loss of $237.1 million a year earlier. Operating margin was -394.9%.
Diluted earnings per share came in at -$1.80. Over the last 5 fiscal years, EDIT's revenue has grown at a -14.9% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Editas Medicine income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.52M | 32.31M | 78.12M | 19.71M | 25.54M | 90.73M | 20.53M | 31.94M | 13.73M | 6.05M |
| Revenue growth (YoY) | +25.39% | -58.64% | +296.32% | -22.83% | -71.85% | +341.93% | -35.71% | +132.64% | +126.80% | — |
| Operating Expenses | 200.53M | 283.47M | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M |
| Research & Development | 89.95M | 199.25M | 177.65M | 174.96M | 142.51M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M |
| Operating Income | -160.01M | -251.15M | -169.18M | -225.95M | -193.15M | -134.84M | -140.92M | -113.73M | -119.93M | -97.19M |
| Interest Expense | 2.13M | 0 | — | — | — | — | — | — | — | — |
| Other Income (Expense) | -50.00K | 14.06M | 15.96M | 5.52M | 644.00K | 18.86M | 7.18M | 3.77M | -391.00K | 5.00K |
| Income Tax | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| Net Income | -160.06M | -237.09M | -153.22M | -220.43M | -192.50M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
| EPS (Diluted) | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
| Shares Outstanding (Basic) | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M |
| Shares Outstanding (Diluted) | 88.75M | 82.34M | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M |
| EBITDA | -154.73M | -245.34M | -163.12M | -219.61M | -188.09M | -130.88M | -138.09M | -110.47M | -117.25M | -95.99M |
| Operating Margin | -394.89% | -777.22% | -216.56% | -1146.26% | -756.13% | -148.61% | -686.39% | -356.10% | -873.64% | -1605.62% |
| Net Margin | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1605.53% |
This table shows 10 annual periods of Editas Medicine's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a income statement?